Cargando…

Immune response to hepatitis B vaccine: An evaluation

BACKGROUND: Hepatitis B virus infection is a major public health problem in India, and all health-care workers (HCWs) need to be immunized to prevent occupational exposure. This study was done to find the hepatitis B vaccination rates, immune response, and predictors of titer <10 mIU/ml among stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhavan, Anitha, Palappallil, Dhanya Sasidharan, Balakrishnapanicker, Jayalakshmy, Asokan, Anjana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525787/
https://www.ncbi.nlm.nih.gov/pubmed/34760649
http://dx.doi.org/10.4103/picr.PICR_119_19
_version_ 1784585752176230400
author Madhavan, Anitha
Palappallil, Dhanya Sasidharan
Balakrishnapanicker, Jayalakshmy
Asokan, Anjana
author_facet Madhavan, Anitha
Palappallil, Dhanya Sasidharan
Balakrishnapanicker, Jayalakshmy
Asokan, Anjana
author_sort Madhavan, Anitha
collection PubMed
description BACKGROUND: Hepatitis B virus infection is a major public health problem in India, and all health-care workers (HCWs) need to be immunized to prevent occupational exposure. This study was done to find the hepatitis B vaccination rates, immune response, and predictors of titer <10 mIU/ml among students and HCWs of a tertiary care institution in the state of Kerala. MATERIALS AND METHODS: This was a cross-sectional study conducted in the Department of Microbiology, Government TD Medical College, Alappuzha, Kerala, India, for a period of 1½ years between January 1, 2016, and June 30, 2017. Vaccination rates were collected through a screening proforma. Of the 1321 participants who filled the screening proforma, 5 ml of blood was collected aseptically from 579 participants who were fully vaccinated (all the three doses of vaccine) and stored at −20°C until antibody to hepatitis B surface antigen (anti-HBs) assay was done using Microlisa (Biorad). Data were analyzed using SPSS for Windows, version 16.0. (SPSS Inc., Chicago, IL, USA) (trial version). STATISTICAL ANALYSIS: Descriptive data were expressed using frequencies and percentages, and Chi-square test was applied to find the association between antibody titer <10 mIU/ml and independent variables. RESULTS: Of the 1321 participants who filled up the screening proforma, the vaccination rate was 72.6%. Majority of the participants, i.e. 83.5% of doctors, 81.1% of nurses, 69.7% of students, and 21.4% of technicians, had taken all the three doses of hepatitis B vaccine. Of the fully vaccinated (n = 959) participants, 76.9% had the vaccination during adulthood and only 26.1% had it during childhood. The correlate of protection was defined as the presence of anti-HBs ≥10 mIU/ml. The mean antibody titer was 448 ± 284.97 mIU/ml ranging from 9.8 to 2000. Of the 579 participants whose titer was checked, 71 (12.3%) had a nonprotective titer of <10 mIU/ml. We found that age >35 (odds ratio [OR]: 3.85, 95% confidence interval [CI]: 2.12–6.99]), last dose >10 years (OR: 5.01, 95% CI: 2.94–8.55), no boosters or revaccination (OR: 2.94, 95% CI: 1.42–6.07), and body mass index (BMI) >25 (OR: 2.51, 95% CI: 1.44–3.39) were associated with nonprotective titer. CONCLUSION: More than a quarter of the study population who were at high risk of exposure were unvaccinated or partially vaccinated. Even after taking the full course of hepatitis B vaccine, 12.3% had titer <10 mIU/ml. Nonprotective titer was found to be associated with age >35 years, last dose taken >10 years ago, no boosters/revaccination, and BMI ≥25.
format Online
Article
Text
id pubmed-8525787
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-85257872021-11-09 Immune response to hepatitis B vaccine: An evaluation Madhavan, Anitha Palappallil, Dhanya Sasidharan Balakrishnapanicker, Jayalakshmy Asokan, Anjana Perspect Clin Res Original Article BACKGROUND: Hepatitis B virus infection is a major public health problem in India, and all health-care workers (HCWs) need to be immunized to prevent occupational exposure. This study was done to find the hepatitis B vaccination rates, immune response, and predictors of titer <10 mIU/ml among students and HCWs of a tertiary care institution in the state of Kerala. MATERIALS AND METHODS: This was a cross-sectional study conducted in the Department of Microbiology, Government TD Medical College, Alappuzha, Kerala, India, for a period of 1½ years between January 1, 2016, and June 30, 2017. Vaccination rates were collected through a screening proforma. Of the 1321 participants who filled the screening proforma, 5 ml of blood was collected aseptically from 579 participants who were fully vaccinated (all the three doses of vaccine) and stored at −20°C until antibody to hepatitis B surface antigen (anti-HBs) assay was done using Microlisa (Biorad). Data were analyzed using SPSS for Windows, version 16.0. (SPSS Inc., Chicago, IL, USA) (trial version). STATISTICAL ANALYSIS: Descriptive data were expressed using frequencies and percentages, and Chi-square test was applied to find the association between antibody titer <10 mIU/ml and independent variables. RESULTS: Of the 1321 participants who filled up the screening proforma, the vaccination rate was 72.6%. Majority of the participants, i.e. 83.5% of doctors, 81.1% of nurses, 69.7% of students, and 21.4% of technicians, had taken all the three doses of hepatitis B vaccine. Of the fully vaccinated (n = 959) participants, 76.9% had the vaccination during adulthood and only 26.1% had it during childhood. The correlate of protection was defined as the presence of anti-HBs ≥10 mIU/ml. The mean antibody titer was 448 ± 284.97 mIU/ml ranging from 9.8 to 2000. Of the 579 participants whose titer was checked, 71 (12.3%) had a nonprotective titer of <10 mIU/ml. We found that age >35 (odds ratio [OR]: 3.85, 95% confidence interval [CI]: 2.12–6.99]), last dose >10 years (OR: 5.01, 95% CI: 2.94–8.55), no boosters or revaccination (OR: 2.94, 95% CI: 1.42–6.07), and body mass index (BMI) >25 (OR: 2.51, 95% CI: 1.44–3.39) were associated with nonprotective titer. CONCLUSION: More than a quarter of the study population who were at high risk of exposure were unvaccinated or partially vaccinated. Even after taking the full course of hepatitis B vaccine, 12.3% had titer <10 mIU/ml. Nonprotective titer was found to be associated with age >35 years, last dose taken >10 years ago, no boosters/revaccination, and BMI ≥25. Wolters Kluwer - Medknow 2021 2020-05-07 /pmc/articles/PMC8525787/ /pubmed/34760649 http://dx.doi.org/10.4103/picr.PICR_119_19 Text en Copyright: © 2020 Perspectives in Clinical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Madhavan, Anitha
Palappallil, Dhanya Sasidharan
Balakrishnapanicker, Jayalakshmy
Asokan, Anjana
Immune response to hepatitis B vaccine: An evaluation
title Immune response to hepatitis B vaccine: An evaluation
title_full Immune response to hepatitis B vaccine: An evaluation
title_fullStr Immune response to hepatitis B vaccine: An evaluation
title_full_unstemmed Immune response to hepatitis B vaccine: An evaluation
title_short Immune response to hepatitis B vaccine: An evaluation
title_sort immune response to hepatitis b vaccine: an evaluation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525787/
https://www.ncbi.nlm.nih.gov/pubmed/34760649
http://dx.doi.org/10.4103/picr.PICR_119_19
work_keys_str_mv AT madhavananitha immuneresponsetohepatitisbvaccineanevaluation
AT palappallildhanyasasidharan immuneresponsetohepatitisbvaccineanevaluation
AT balakrishnapanickerjayalakshmy immuneresponsetohepatitisbvaccineanevaluation
AT asokananjana immuneresponsetohepatitisbvaccineanevaluation